The general scope of the book is the patentability and morality of human
embryonic stem cell research in US, EU and China. The book observes
fraudsters operate unsafe human embryonic stem cell therapies and
officialdom turns a blind eye to the immoral human embryonic stem cell
research in China. The book highlights that both patent control and
federal funding control are inefficient and ineffective way to
monitoring human embryonic stem cell research. The book finally proposed
an approach for china to regulating human embryonic stem cell
research-regulating research itself at the reconciled international
regime.
The potential reader includes academics and practitioners dealing with
intellectual property, patent law and stem cell inventions. The topic
discussed will also be interesting to a broad readership, including
experts, regulators, policy makers and medical researchers in both
ethical and legal disciplines in the field of embryonic stem cell
research.
